Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aveo Pharmaceuticals (NQ: AVEO )

5.170 USD +0.020 (+0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 172,266
Open 5.140
Bid (Size) 5.050 (1)
Ask (Size) 5.270 (2)
Prev. Close 5.150
Today's Range 5.050 - 5.220
52wk Range 4.130 - 18.24
Shares Outstanding 34,360,775
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05,... 
From Business Wire News Releases
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) webinar focusing on FOTIVDA®... 
From Business Wire News Releases

Performance

YTD
-13.40%
-13.40%
1 Month
-17.94%
-17.94%
3 Month
-29.47%
-29.47%
6 Month
-35.05%
-35.05%
1 Year
+21.36%
+21.36%

More News

Read More
AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma
From Business Wire News Releases
AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference
From Business Wire News Releases
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
From Business Wire News Releases
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
From Business Wire News Releases
AVEO Pharmaceuticals Becomes Oversold (AVEO)
Tags Stocks
From Market News Video
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
From Business Wire News Releases
AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
From Business Wire News Releases
AVEO Pharmaceuticals Enters Oversold Territory (AVEO)
Tags Stocks
From Market News Video
Notable Two Hundred Day Moving Average Cross - AVEO
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.